Bioequivalence Study of Ezetimibe Tablets After a Single Oral Dose of 10 mg in Healthy Japanese Subjects Under Fasting Conditions
Clinical Pharmacology in Drug Development · 2023
DOI: 10.1002/cpdd.1245 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Clinical Pharmacology in Drug Development, 2023. Verfasst von Shigenori Wada und 3 weiteren Autor:innen. Beteiligte Einrichtung: Development Department, Nihon Generic Co., Ltd., Tokyo, Japan. Hauptthemen laut MEDLINE: East Asian People, Fasting, Therapeutic Equivalency, Drugs, Generic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 17 Literaturangaben.
Abstract (Originalsprache)
This study compared the pharmacokinetic and safety profiles between a new generic and a branded reference product of 10‐mg ezetimibe (EZE) tablets in 24 healthy Japanese male volunteers under fasting conditions, obtaining sufficient evidence for the marketing approval of the new generic product. The bioequivalence study was conducted with an open‐label, 2 × 2, single‐dose, crossover design in which the test and reference products were administered to volunteers after fasting for ≥10 hours. Blood samples were collected 24 times before to 72 hours after the administration of the investigational drug. We evaluated the peak drug concentration and the area under the plasma concentration–time curve up to the last measured concentration of EZE, EZEG, and total EZE (EZE + ezetimibe glucuronide [EZEG]). The 90% confidence intervals of the geometric mean ratios for peak drug concentration and area under the plasma concentration–time curve up to the last measured concentration of the test and reference products fell within the bioequivalence limits of 0.80 to 1.25 for EZE, EZEG, and total EZE. The test and reference products were well tolerated, and no adverse events occurred during the study. The test product was bioequivalent to the reference product.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Development Department, Nihon Generic Co., Ltd., Tokyo, Japan.
Zitieren
APA
Wada, S., Sasagane, Y., Kagatani, S., & Nakagami, H. (2023). Bioequivalence Study of Ezetimibe Tablets After a Single Oral Dose of 10 mg in Healthy Japanese Subjects Under Fasting Conditions. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1245
Vancouver
Wada S, Sasagane Y, Kagatani S, Nakagami H. Bioequivalence Study of Ezetimibe Tablets After a Single Oral Dose of 10 mg in Healthy Japanese Subjects Under Fasting Conditions. Clinical Pharmacology in Drug Development. 2023. doi:10.1002/cpdd.1245
BibTeX
@article{Wada2023,
author = {Wada, Shigenori and Sasagane, Yoshiyuki and Kagatani, Seiya and Nakagami, Hiroaki},
title = {Bioequivalence Study of Ezetimibe Tablets After a Single Oral Dose of 10 mg in Healthy Japanese Subjects Under Fasting Conditions},
journal = {Clinical Pharmacology in Drug Development},
year = {2023},
doi = {10.1002/cpdd.1245}
}
EUVIMED